Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review

P Ozieranski, L Martinon, PA Jachiet, S Mulinari - BMJ open, 2021 - bmjopen.bmj.com
Objectives To examine the accessibility and quality of drug company payment data in
Europe. Design Comparative policy review of payment data in countries with different …

Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform

T Torgerson, C Wayant, L Cosgrove, EA Akl… - BMJ evidence-based …, 2022 - ebm.bmj.com
Conflicts of interest (COIs) in healthcare are increasingly discussed in the literature, yet
these relationships continue to influence healthcare. Research has consistently shown that …

[HTML][HTML] International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and …

P Ozieranski, H Saito, E Rickard, S Mulinari… - Globalization and …, 2023 - Springer
Background Self-regulation of payment disclosure by pharmaceutical industry trade groups
is a major global approach to increasing transparency of financial relationships between …

Nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in Japan between 2016 and 2019

A Murayama, M Hoshi, H Saito, S Kamamoto… - Respiration, 2022 - karger.com
Background: Financial relationships between healthcare professionals and pharmaceutical
companies have historically caused conflicts of interest and unduly influenced patient care …

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019

A Murayama, S Kamamoto, M Kawashima, H Saito… - BMJ open, 2023 - bmjopen.bmj.com
Objectives Limited evidence is available regarding the financial relationships between
gastroenterologists and pharmaceutical companies in Japan. This study analysed the …

Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of …

A Ozaki, H Saito, Y Senoo, T Sawano, Y Shimada… - Health Policy, 2020 - Elsevier
Objective To provide an overview of non-research pharmaceutical payments to healthcare
organizations and professionals in Japan and evaluate data disclosure methods. Methods …

[HTML][HTML] Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven …

S Mulinari, L Martinon, PA Jachiet, P Ozieranski - Health Policy, 2021 - Elsevier
The European pharmaceutical industry uses the alleged efficacy of self-regulation to
question the need for transparency laws similar to the US Physician Payment Sunshine Act …

[HTML][HTML] Characteristics and distribution of scholarship donations from pharmaceutical companies to Japanese Healthcare institutions in 2017: A cross-sectional …

A Murayama, S Kamamoto, H Saito… - … Journal of Health …, 2023 - ncbi.nlm.nih.gov
Background: Financial relationships between healthcare institutions and pharmaceutical
companies can lead to conflicts of interest (COIs), potentially compromising patients' care. In …

[HTML][HTML] Assessment of financial relationships between otorhinolaryngologists and pharmaceutical companies in Japan between 2016 and 2019

S Kamamoto, A Ozaki, A Murayama - Cureus, 2023 - ncbi.nlm.nih.gov
Introduction: There are prevalent financial relationships between physicians and the
pharmaceutical industry in medical specialties, including otorhinolaryngology. Although …

Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan

K Yamamoto, A Murayama, A Ozaki, H Saito… - International …, 2021 - Springer
Abstract Introduction and hypothesis In Japan, the authors of urology clinical practice
guidelines (UCPG) used in patient-centered care are often targeted by pharmaceutical …